Are ex vivo neutralizing antibodies against IFN always detrimental to therapeutic efficacy in multiple sclerosis?

PS Sørensen, N Koch-Henriksen, K Bendtzen, Egon Stenager

Research output: Contribution to journalJournal articleResearchpeer-review

Original languageEnglish
JournalMultiple sclerosis
Volume13
Issue number5
Pages (from-to)616-621
Number of pages6
ISSN1352-4585
Publication statusPublished - 2007

Cite this